{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T19:53:59Z","timestamp":1770321239213,"version":"3.49.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00428-025-04320-1","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:57:58Z","timestamp":1761717478000},"page":"65-77","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Differential diagnosis and predictive markers of pancreatic neuroendocrine tumours (PanNET)"],"prefix":"10.1007","volume":"488","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-4657","authenticated-orcid":false,"given":"Matthieu","family":"Tihy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agathe","family":"Hercent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Cros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Couvelard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"4320_CR1","unstructured":"Osamura RY, Washington MK, Mete O et al (2025) Chapter 7: Pancreatic neuroendocrine neoplasms. In: WHO classification of tumours editorial board endocrine and neuroendocrine tumours. Lyon (France): International Agency for Research on Cancer. (WHO classification of tumours series, 5th edn, vol 10). https:\/\/publications.iarc.who.int\/645"},{"key":"4320_CR2","unstructured":"WHO Classification of Tumours Editorial Board (2019) Digestive system tumours. Lyon (France): International Agency for Research on Cancer. (WHO classification of tumours series, 5th edn, vol 1). https:\/\/publications.iarc.fr\/579"},{"issue":"5","key":"4320_CR3","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.hpb.2018.09.016","volume":"21","author":"A Pulvirenti","year":"2019","unstructured":"Pulvirenti A, Rao D, Mcintyre CA, Gonen M, Tang LH, Klimstra DS et al (2019) Limited role of chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors. HPB (Oxford) 21(5):612\u2013618","journal-title":"HPB (Oxford)"},{"issue":"3","key":"4320_CR4","first-page":"211","volume":"117","author":"P Chatzipantelis","year":"2009","unstructured":"Chatzipantelis P, Konstantinou P, Kaklamanos M, Apostolou G, Salla C (2009) The role of cytomorphology and proliferative activity in predicting biologic behavior of pancreatic neuroendocrine tumors: a study by endoscopic ultrasound-guided fine-needle aspiration cytology. Cancer 117(3):211\u2013216","journal-title":"Cancer"},{"issue":"3","key":"4320_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ando.2019.04.010","volume":"80","author":"A Scarpa","year":"2019","unstructured":"Scarpa A (2019) The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours. Ann Endocrinol (Paris) 80(3):153\u2013158","journal-title":"Ann Endocrinol (Paris)"},{"issue":"1","key":"4320_CR6","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s42003-020-01479-y","volume":"3","author":"A Di Domenico","year":"2020","unstructured":"Di Domenico A, Pipinikas CP, Maire RS, Br\u00e4utigam K, Simillion C, Dettmer MS et al (2020) Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression. Commun Biol 3(1):740","journal-title":"Commun Biol"},{"issue":"1","key":"4320_CR7","doi-asserted-by":"publisher","first-page":"R37","DOI":"10.1530\/JME-12-0069","volume":"49","author":"G Capurso","year":"2012","unstructured":"Capurso G, Festa S, Valente R, Piciucchi M, Panzuto F, Jensen RT et al (2012) Molecular pathology and genetics of pancreatic endocrine tumours. J Mol Endocrinol 49(1):R37\u201350","journal-title":"J Mol Endocrinol"},{"issue":"7643","key":"4320_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nature21063","volume":"543","author":"A Scarpa","year":"2017","unstructured":"Scarpa A, Nones K, Corbo V, Patch AM, Bailey P, Lawlor RT et al (2017) Whole-genome landscape of pancreatic neuroendocrine tumours. Nature 543(7643):65\u201371","journal-title":"Nature"},{"issue":"46","key":"4320_CR9","doi-asserted-by":"publisher","first-page":"e36094","DOI":"10.1097\/MD.0000000000036094","volume":"102","author":"Y Alshareefy","year":"2023","unstructured":"Alshareefy Y, Cummins S, Mazzoleni A, Sharma V, Guggilapu S, Leong AWY et al (2023) A review of functional pancreatic neuroendocrine tumors: exploring the molecular pathogenesis, diagnosis and treatment. Medicine (Baltimore) 102(46):e36094","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"4320_CR10","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/s41379-022-01110-x","volume":"35","author":"T Depoilly","year":"2022","unstructured":"Depoilly T, Leroux R, Andrade D, Nicolle R, Dioguardi Burgio M, Marinoni I et al (2022) Immunophenotypic and molecular characterization of pancreatic neuroendocrine tumors producing serotonin. Mod Pathol 35(11):1713\u20131722","journal-title":"Mod Pathol"},{"issue":"11","key":"4320_CR11","doi-asserted-by":"publisher","first-page":"8671","DOI":"10.1007\/s00330-021-08007-4","volume":"31","author":"M Dioguardi Burgio","year":"2021","unstructured":"Dioguardi Burgio M, Cros J, Panvini N, Depoilly T, Couvelard A, Ruszniewski P et al (2021) Serotonin immunoreactive pancreatic neuroendocrine neoplasm associated with main pancreatic duct dilation: a recognizable entity with excellent long-term outcome. Eur Radiol 31(11):8671\u20138681","journal-title":"Eur Radiol"},{"issue":"3","key":"4320_CR12","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/PAS.0000000000000340","volume":"39","author":"R Maragliano","year":"2015","unstructured":"Maragliano R, Vanoli A, Albarello L, Milione M, Basturk O, Klimstra DS et al (2015) ACTH-secreting pancreatic neoplasms associated with Cushing syndrome: clinicopathologic study of 11 cases and review of the literature. Am J Surg Pathol 39(3):374\u2013382","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"4320_CR13","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1677\/ERC-10-0037","volume":"17","author":"Z Erlic","year":"2010","unstructured":"Erlic Z, Ploeckinger U, Cascon A, Hoffmann MM, von Duecker L, Winter A et al (2010) Systematic comparison of sporadic and syndromic pancreatic islet cell tumors. Endocr Relat Cancer 17(4):875\u2013883","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"4320_CR14","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.3390\/cancers16112075","volume":"16","author":"N Papadopoulou-Marketou","year":"2024","unstructured":"Papadopoulou-Marketou N, Tsoli M, Chatzellis E, Alexandraki KI, Kaltsas G (2024) Hereditary syndromes associated with pancreatic and lung neuroendocrine tumors. Cancers (Basel) 16(11):2075","journal-title":"Cancers (Basel)"},{"issue":"2","key":"4320_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/cen.13264","volume":"86","author":"D Donegan","year":"2017","unstructured":"Donegan D, Singh Ospina N, Rodriguez-Gutierrez R, Al-Hilli Z, Thompson GB, Clarke BL et al (2017) Long-term outcomes in patients with multiple endocrine neoplasia type 1 and pancreaticoduodenal neuroendocrine tumours. Clin Endocrinol (Oxf) 86(2):199\u2013206","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"4320_CR16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/cen.14727","volume":"97","author":"CRC Pieterman","year":"2022","unstructured":"Pieterman CRC, Valk GD (2022) Update on the clinical management of multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf) 97(4):409\u2013423","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"4320_CR17","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1530\/ERC-18-0100","volume":"25","author":"T Krauss","year":"2018","unstructured":"Krauss T, Ferrara AM, Links TP, Wellner U, Bancos I, Kvachenyuk A et al (2018) Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors. Endocr Relat Cancer 25(9):783\u2013793","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"4320_CR18","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1159\/000511905","volume":"111","author":"H Elvebakken","year":"2021","unstructured":"Elvebakken H, Perren A, Scoazec JY, Tang LH, Federspiel B, Klimstra DS et al (2021) A consensus-developed morphological re-evaluation of 196 high-grade gastroenteropancreatic neuroendocrine neoplasms and its clinical correlations. Neuroendocrinology 111(9):883\u2013894","journal-title":"Neuroendocrinology"},{"issue":"1","key":"4320_CR19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000445165","volume":"104","author":"M Milione","year":"2017","unstructured":"Milione M, Maisonneuve P, Spada F, Pellegrinelli A, Spaggiari P, Albarello L et al (2017) The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories. Neuroendocrinology 104(1):85\u201393","journal-title":"Neuroendocrinology"},{"issue":"6021","key":"4320_CR20","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1126\/science.1200609","volume":"331","author":"Y Jiao","year":"2011","unstructured":"Jiao Y, Shi C, Edil BH, De Wilde RF, Klimstra DS, Maitra A et al (2011) DAXX \/ ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331(6021):1199\u20131203","journal-title":"Science"},{"issue":"9","key":"4320_CR21","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1097\/PAS.0000000000000662","volume":"40","author":"LH Tang","year":"2016","unstructured":"Tang LH, Basturk O, Sue JJ, Klimstra DS (2016) A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol 40(9):1192\u20131202","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"4320_CR22","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/modpathol.2016.217","volume":"30","author":"B Konukiewitz","year":"2017","unstructured":"Konukiewitz B, Schlitter AM, Jesinghaus M, Pfister D, Steiger K, Segler A et al (2017) Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20. Mod Pathol 30(4):587\u2013598","journal-title":"Mod Pathol"},{"issue":"2","key":"4320_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00428-021-03202-6","volume":"480","author":"A Kasajima","year":"2022","unstructured":"Kasajima A, Konukiewitz B, Schlitter AM, Weichert W, Kl\u00f6ppel G (2022) An analysis of 130 neuroendocrine tumors G3 regarding prevalence, origin, metastasis, and diagnostic features. Virchows Arch 480(2):359\u2013368","journal-title":"Virchows Arch"},{"issue":"3","key":"4320_CR24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/modpathol.3880044","volume":"13","author":"SN Agoff","year":"2000","unstructured":"Agoff SN, Lamps LW, Philip AT, Amin MB, Schmidt RA, True LD et al (2000) Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol 13(3):238\u2013242","journal-title":"Mod Pathol"},{"issue":"1","key":"4320_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA et al (2022) Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol 33(1):115\u2013154","journal-title":"Endocr Pathol"},{"issue":"5","key":"4320_CR26","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1530\/ERC-17-0557","volume":"25","author":"M Milione","year":"2018","unstructured":"Milione M, Maisonneuve P, Pellegrinelli A, Grillo F, Albarello L, Spaggiari P et al (2018) Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis. Endocr Relat Cancer 25(5):583\u2013593","journal-title":"Endocr Relat Cancer"},{"key":"4320_CR27","unstructured":"Sylla A, Hervieu V, Lombard-Bohas C, Tani\u00e8re P, Elbaz N, Scoazec JY (2003) Amphicrine carcinoma of the pancreas. Report of two cases. Ann Pathol 23(5):424\u2013429"},{"issue":"2","key":"4320_CR28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s12022-023-09766-0","volume":"34","author":"H Watanabe","year":"2023","unstructured":"Watanabe H, Yamazaki Y, Miura S, Higuchi S, Fujishima F (2023) Mucinous amphicrine carcinoma of the pancreas: a diagnostic pitfall. Endocr Pathol 34(2):267\u2013270","journal-title":"Endocr Pathol"},{"issue":"1","key":"4320_CR29","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s12328-021-01552-x","volume":"15","author":"S Hiroi","year":"2022","unstructured":"Hiroi S, Yamamoto R, Hamaoka M, Hoshino M, Sasaki T, Matsugu Y et al (2022) Mixed neuroendocrine non-neuroendocrine neoplasm: a case report and review. Clin J Gastroenterol 15(1):244\u2013255","journal-title":"Clin J Gastroenterol"},{"issue":"1","key":"4320_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13000-017-0648-x","volume":"12","author":"K Nonaka","year":"2017","unstructured":"Nonaka K, Matsuda Y, Okaniwa A, Kasajima A, Sasano H, Arai T (2017) Pancreatic gangliocytic paraganglioma harboring lymph node metastasis: a case report and literature review. Diagn Pathol 12(1):57","journal-title":"Diagn Pathol"},{"key":"4320_CR31","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.humpath.2020.07.010","volume":"103","author":"D Mamilla","year":"2020","unstructured":"Mamilla D, Manukyan I, Fetsch PA, Pacak K, Miettinen M (2020) Immunohistochemical distinction of paragangliomas from epithelial neuroendocrine tumors-gangliocytic duodenal and cauda equina paragangliomas align with epithelial neuroendocrine tumors. Hum Pathol 103:72\u201382","journal-title":"Hum Pathol"},{"key":"4320_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.humpath.2019.12.002","volume":"96","author":"AM Bellizzi","year":"2020","unstructured":"Bellizzi AM (2020) Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you? Hum Pathol 96:8\u201333","journal-title":"Hum Pathol"},{"issue":"5","key":"4320_CR33","doi-asserted-by":"publisher","first-page":"101795","DOI":"10.1016\/j.beem.2023.101795","volume":"37","author":"A Couvelard","year":"2023","unstructured":"Couvelard A, Cazes A, Cros J (2023) Updates in histopathological classification and tissue biomarkers of digestive neuroendocrine neoplasms: what the clinician should know. Best Pract Res Clin Endocrinol Metab 37(5):101795","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"4320_CR34","doi-asserted-by":"publisher","first-page":"105695","DOI":"10.1016\/j.humpath.2024.105695","volume":"154","author":"F Lutz","year":"2024","unstructured":"Lutz F, Hornburg SM, M\u00f6ller K, Viehweger F, Schlichter R, Menz A et al (2024) PAX6 is a useful marker for pancreatic origin of neuroendocrine neoplasms: a tissue microarray study evaluating more than 19,000 tumors from 150 different tumor types. Hum Pathol 154:105695","journal-title":"Hum Pathol"},{"issue":"7","key":"4320_CR35","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1097\/PAS.0000000000000876","volume":"41","author":"Z Yang","year":"2017","unstructured":"Yang Z, Klimstra DS, Hruban RH, Tang LH (2017) Immunohistochemical characterization of the origins of metastatic well-differentiated neuroendocrine tumors to the liver. Am J Surg Pathol 41(7):915\u2013922","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"4320_CR36","doi-asserted-by":"publisher","first-page":"152448","DOI":"10.1016\/j.prp.2019.152448","volume":"215","author":"LH Zhao","year":"2019","unstructured":"Zhao LH, Chen C, Mao CY, Xiao H, Fu P, Xiao HL et al (2019) Value of SATB2, ISL1, and TTF1 to differentiate rectal from other gastrointestinal and lung well-differentiated neuroendocrine tumors. Pathol Res Pract 215(7):152448","journal-title":"Pathol Res Pract"},{"issue":"7","key":"4320_CR37","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1177\/10668969231157319","volume":"31","author":"Y Xiang","year":"2023","unstructured":"Xiang Y, Malik F, Zhang PJ (2023) Islet-1 is differentially expressed among neuroendocrine and non-neuroendocrine tumors and its potential diagnostic implication. Int J Surg Pathol 31(7):1294\u20131301","journal-title":"Int J Surg Pathol"},{"key":"4320_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.humpath.2022.07.015","volume":"129","author":"CM Heaphy","year":"2022","unstructured":"Heaphy CM, Singhi AD (2022) The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors. Hum Pathol 129:11\u201320","journal-title":"Hum Pathol"},{"issue":"4","key":"4320_CR39","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/PAS.0000000000002186","volume":"48","author":"M Lennartz","year":"2024","unstructured":"Lennartz M, Benjamin D\u00fcnnebier N, H\u00f6flmayer D, Dwertmann Rico S, Kind S, Reiswich V et al (2024) GAD2 is a highly specific marker for neuroendocrine neoplasms of the pancreas. Am J Surg Pathol 48(4):377\u2013386","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"4320_CR40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/PAS.0000000000002154","volume":"48","author":"MA Pepper","year":"2024","unstructured":"Pepper MA, Dulken BW, Wang Y, Zemek AJ, Martin BA, Charu V et al (2024) S100 Protein expression in primary and metastatic neuroendocrine neoplasms: a specific marker of pancreatic origin. Am J Surg Pathol 48(2):157\u2013162","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"4320_CR41","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1097\/PAS.0b013e318263209d","volume":"36","author":"S La Rosa","year":"2012","unstructured":"La Rosa S, Adsay V, Albarello L, Asioli S, Casnedi S, Franzi F et al (2012) Clinicopathologic study of 62 acinar cell carcinomas of the pancreas: insights into the morphology and immunophenotype and search for prognostic markers. Am J Surg Pathol 36(12):1782\u20131795","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"4320_CR42","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/PAS.0000000000002024","volume":"47","author":"U Ishimoto-Namiki","year":"2023","unstructured":"Ishimoto-Namiki U, Ino Y, Esaki M, Shimada K, Saruta M, Hiraoka N (2023May 1) Novel insights into immunohistochemical analysis for acinar cell neoplasm of the pancreas: carboxypeptidase A2, carboxypeptidase A1, and glycoprotein 2. Am J Surg Pathol 47(5):525\u2013534","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"4320_CR43","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00428-008-0710-x","volume":"454","author":"S La Rosa","year":"2009","unstructured":"La Rosa S, Franzi F, Marchet S, Finzi G, Clerici M, Vigetti D et al (2009) The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasia. Virchows Arch 454(2):133\u2013142","journal-title":"Virchows Arch"},{"issue":"3","key":"4320_CR44","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S0002-9440(10)64917-6","volume":"160","author":"SC Abraham","year":"2002","unstructured":"Abraham SC, Wu TT, Hruban RH, Lee JH, Yeo CJ, Conlon K et al (2002) Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC\/beta-catenin pathway. Am J Pathol 160(3):953\u2013962","journal-title":"Am J Pathol"},{"issue":"4","key":"4320_CR45","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1385\/EP:14:4:293","volume":"14","author":"RV Lloyd","year":"2003","unstructured":"Lloyd RV (2003) Practical markers used in the diagnosis of neuroendocrine tumors. EP 14(4):293\u2013302","journal-title":"EP"},{"issue":"10","key":"4320_CR46","doi-asserted-by":"publisher","first-page":"100810","DOI":"10.1016\/j.modpat.2025.100810","volume":"38","author":"J Fern\u00e1ndez-P\u00e9rez","year":"2025","unstructured":"Fern\u00e1ndez-P\u00e9rez J, Pommepuy I, Michal M, Michal M, Cleven AHG, Bouvier C et al (2025) Deciphering pseudoendocrine sarcoma: a clinicopathological, molecular, and epigenetic study suggesting biological links with solid pseudopapillary neoplasm of the pancreas. Mod Pathol 38(10):100810","journal-title":"Mod Pathol"},{"issue":"8","key":"4320_CR47","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1002\/1878-0261.12490","volume":"13","author":"P Selenica","year":"2019","unstructured":"Selenica P, Raj N, Kumar R, Brown DN, Arqu\u00e9s O, Reidy D et al (2019) Solid pseudopapillary neoplasms of the pancreas are dependent on the Wnt pathway. Mol Oncol 13(8):1684\u20131692","journal-title":"Mol Oncol"},{"key":"4320_CR48","doi-asserted-by":"crossref","unstructured":"Kim MJ, Jang SJ, Eunsil Yu (2008) Loss of E-cadherin and cytoplasmic-nuclear expression of beta-catenin are the most useful immunoprofiles in the diagnosis of solid-pseudopapillary neoplasm of the pancreas. Hum Pathol 39(2):251\u2013258","DOI":"10.1016\/j.humpath.2007.06.014"},{"issue":"38","key":"4320_CR49","doi-asserted-by":"publisher","first-page":"8596","DOI":"10.3748\/wjg.v22.i38.8596","volume":"22","author":"Y Ohara","year":"2016","unstructured":"Ohara Y, Oda T, Hashimoto S, Akashi Y, Miyamoto R, Enomoto T et al (2016) Pancreatic neuroendocrine tumor and solid-pseudopapillary neoplasm: key immunohistochemical profiles for differential diagnosis. World J Gastroenterol 22(38):8596\u20138604","journal-title":"World J Gastroenterol"},{"issue":"2","key":"4320_CR50","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1440-1746.2010.06466.x","volume":"26","author":"NQ Nguyen","year":"2011","unstructured":"Nguyen NQ, Johns AL, Gill AJ, Ring N, Chang DK, Clarkson A et al (2011) Clinical and immunohistochemical features of 34 solid pseudopapillary tumors of the pancreas. J Gastroenterol Hepatol 26(2):267\u2013274","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"4320_CR51","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/PAS.0000000000002205","volume":"48","author":"YA Liu","year":"2024","unstructured":"Liu YA, Liu Y, Tu J, Shi Y, Pang J, Huang Q et al (2024) ABCD1 as a novel diagnostic marker for solid pseudopapillary neoplasm of the pancreas. Am J Surg Pathol 48(5):511\u2013520","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"4320_CR52","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12957-016-0771-2","volume":"14","author":"S Lin","year":"2016","unstructured":"Lin S, Peng L, Huang S, Li Y, Xiao W (2016) Primary pancreatic paraganglioma: a case report and literature review. World J Surg Oncol 14(1):19","journal-title":"World J Surg Oncol"},{"issue":"3","key":"4320_CR53","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/PAI.0000000000000715","volume":"28","author":"K Kriegsmann","year":"2020","unstructured":"Kriegsmann K, Zgorzelski C, Kazdal D, Cremer M, Muley T, Winter H et al (2020) Insulinoma-associated protein 1 (INSM1) in thoracic tumors is less sensitive but more specific compared with synaptophysin, chromogranin A, and CD56. Appl Immunohistochem Mol Morphol 28(3):237\u2013242","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"4320_CR54","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.humpath.2019.08.013","volume":"93","author":"JK Dermawan","year":"2019","unstructured":"Dermawan JK, Mukhopadhyay S, Shah AA (2019) Frequency and extent of cytokeratin expression in paraganglioma: an immunohistochemical study of 60 cases from 5 anatomic sites and review of the literature. Hum Pathol 93:16\u201322","journal-title":"Hum Pathol"},{"issue":"5","key":"4320_CR55","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1136\/gutjnl-2020-322595","volume":"71","author":"WM Hackeng","year":"2022","unstructured":"Hackeng WM, Brosens LAA, Kim JY, O\u2019Sullivan R, Sung YN, Liu TC et al (2022) Non-functional pancreatic neuroendocrine tumours: ATRX\/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX\/PDX1 expression and tumour size. Gut 71(5):961\u2013973","journal-title":"Gut"},{"issue":"9","key":"4320_CR56","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1038\/bjc.2013.156","volume":"108","author":"MS Khan","year":"2013","unstructured":"Khan MS, Luong TV, Watkins J, Toumpanakis C, Caplin ME, Meyer T (2013) A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. Br J Cancer 108(9):1838\u20131845","journal-title":"Br J Cancer"},{"issue":"3","key":"4320_CR57","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000457956","volume":"105","author":"A Perren","year":"2017","unstructured":"Perren A, Couvelard A, Scoazec JY, Costa F, Borbath I, Delle Fave G et al (2017) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pathology: diagnosis and prognostic stratification. Neuroendocrinology 105(3):196\u2013200","journal-title":"Neuroendocrinology"},{"issue":"3","key":"4320_CR58","doi-asserted-by":"publisher","first-page":"e240321","DOI":"10.1530\/ERC-24-0321","volume":"32","author":"P Bourdeleau","year":"2025","unstructured":"Bourdeleau P, Pokossy-Ep\u00e9e J, Hentic O, Tihy M, Awan ZA, Couvelard A et al (2025) Temporal increase in Ki-67 index in patients with pancreatic neuroendocrine tumours. Endocr Relat Cancer 32(3):e240321","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"4320_CR59","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000524920","volume":"90","author":"DM Gisder","year":"2023","unstructured":"Gisder DM, Overheu O, Keller J, N\u00f6pel-D\u00fcnnebacke S, Uhl W, Reinacher-Schick A et al (2023) DAXX, ATRX, and MSI in PanNET and their metastases: correlation with histopathological data and prognosis. Pathobiology 90(2):71\u201380","journal-title":"Pathobiology"},{"issue":"3","key":"4320_CR60","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/MPA.0000000000001256","volume":"48","author":"JF Hechtman","year":"2019","unstructured":"Hechtman JF, Klimstra DS, Nanjangud G, Frosina D, Shia J, Jungbluth AA (2019) Performance of DAXX immunohistochemistry as a screen for DAXX mutations in pancreatic neuroendocrine tumors. Pancreas 48(3):396\u2013399","journal-title":"Pancreas"},{"issue":"6","key":"4320_CR61","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1158\/1078-0432.CCR-16-1147","volume":"23","author":"JY Kim","year":"2017","unstructured":"Kim JY, Brosnan-Cashman JA, An S, Kim SJ, Song KB, Kim MS et al (2017) Alternative lengthening of telomeres in primary pancreatic neuroendocrine tumors is associated with aggressive clinical behavior and poor survival. Clin Cancer Res 23(6):1598\u20131606","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4320_CR62","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1053\/j.gastro.2013.10.020","volume":"146","author":"I Marinoni","year":"2014","unstructured":"Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V et al (2014) Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology 146(2):453\u2013460.e5","journal-title":"Gastroenterology"},{"issue":"3","key":"4320_CR63","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1530\/ERC-18-0494","volume":"26","author":"F B\u00f6sch","year":"2019","unstructured":"B\u00f6sch F, Br\u00fcwer K, Altendorf-Hofmann A, Auernhammer CJ, Spitzweg C, Westphalen CB et al (2019) Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia. Endocr Relat Cancer 26(3):293\u2013301","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"4320_CR64","doi-asserted-by":"publisher","first-page":"24669","DOI":"10.1038\/s41598-024-75882-4","volume":"14","author":"Z Chen","year":"2024","unstructured":"Chen Z, Lin S, Liang F, Hou Z, Yang Y, Huang H et al (2024) The prognostic and therapeutic value of the tumor microenvironment and immune checkpoints in pancreatic neuroendocrine neoplasms. Sci Rep 14(1):24669","journal-title":"Sci Rep"},{"issue":"4","key":"4320_CR65","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0016-5085(03)01198-3","volume":"125","author":"AM Marion-Audibert","year":"2003","unstructured":"Marion-Audibert AM, Barel C, Gouysse G, Dumortier J, Pilleul F, Pourreyron C et al (2003) Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology 125(4):1094\u20131104","journal-title":"Gastroenterology"},{"issue":"1","key":"4320_CR66","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/sj.bjc.6602245","volume":"92","author":"A Couvelard","year":"2005","unstructured":"Couvelard A, O\u2019Toole D, Turley H, Leek R, Sauvanet A, Degott C et al (2005) Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 92(1):94\u2013101","journal-title":"Br J Cancer"},{"key":"4320_CR67","doi-asserted-by":"publisher","unstructured":"Sorbye H, Hjortland GO, Vestermark LW et al (2025) Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study. Br J Cancer 133:316\u2013324. https:\/\/doi.org\/10.1038\/s41416-025-03054-w","DOI":"10.1038\/s41416-025-03054-w"},{"issue":"3","key":"4320_CR68","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s00259-016-3486-2","volume":"44","author":"P Brunner","year":"2017","unstructured":"Brunner P, J\u00f6rg AC, Glatz K, Bubendorf L, Radojewski P, Umlauft M et al (2017) The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors. Eur J Nucl Med Mol Imaging 44(3):468\u2013475","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"4320_CR69","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1530\/EJE-22-0339","volume":"187","author":"C Campana","year":"2022","unstructured":"Campana C, van Koetsveld PM, Feelders RA, de Herder WW, Iyer AM, van Velthuysen MLF et al (2022) Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study. Eur J Endocrinol 187(3):399\u2013411","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"4320_CR70","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3390\/cancers14030775","volume":"14","author":"H Watanabe","year":"2022","unstructured":"Watanabe H, Fujishima F, Komoto I, Imamura M, Hijioka S, Hara K et al (2022) Somatostatin receptor 2 expression profiles and their correlation with the efficacy of somatostatin analogues in gastrointestinal neuroendocrine tumors. Cancers (Basel) 14(3):775","journal-title":"Cancers (Basel)"},{"issue":"9","key":"4320_CR71","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.3390\/cancers13092035","volume":"13","author":"AK Elf","year":"2021","unstructured":"Elf AK, Johanson V, Marin I, Bergstr\u00f6m A, Nilsson O, Svensson J et al (2021) Evaluation of SSTR2 expression in SI-NETs and relation to overall survival after PRRT. Cancers 13(9):2035","journal-title":"Cancers"},{"issue":"1","key":"4320_CR72","doi-asserted-by":"publisher","first-page":"E66","DOI":"10.1210\/jc.2012-2609","volume":"98","author":"F Gatto","year":"2013","unstructured":"Gatto F, Feelders RA, Van Der Pas R, Kros JM, Waaijers M, Sprij-Mooij D et al (2013) Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metab 98(1):E66\u201371","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"4320_CR73","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.3390\/curroncol30020106","volume":"30","author":"N Brighi","year":"2023","unstructured":"Brighi N, Lamberti G, Andrini E, Mosconi C, Manuzzi L, Donati G et al (2023) Prospective evaluation of MGMT-promoter methylation status and correlations with outcomes to temozolomide-based chemotherapy in well-differentiated neuroendocrine tumors. Curr Oncol 30(2):1381\u20131394","journal-title":"Curr Oncol"},{"issue":"8","key":"4320_CR74","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1530\/ERC-16-0117","volume":"23","author":"J Cros","year":"2016","unstructured":"Cros J, Hentic O, Rebours V, Zappa M, Gille N, Theou-Anton N et al (2016) MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors. Endocr Relat Cancer 23(8):625\u2013633","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"4320_CR75","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/bjc.2014.660","volume":"112","author":"T Walter","year":"2015","unstructured":"Walter T, van Brakel B, Vercherat C, Hervieu V, Forestier J, Chayvialle JA et al (2015) O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents. Br J Cancer 112(3):523\u2013531","journal-title":"Br J Cancer"},{"issue":"8","key":"4320_CR76","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1200\/JCO.23.02724","volume":"43","author":"T Walter","year":"2025","unstructured":"Walter T, Lecomte T, Hadoux J, Niccoli P, Saban-Roche L, Gaye E et al (2025) Oxaliplatin-based versus alkylating agent in neuroendocrine tumors according to the O6 -methylguanine-DNA methyltransferase status: a randomized phase II study (MGMT-NET). JCO 43(8):960\u2013971","journal-title":"JCO"},{"issue":"7","key":"4320_CR77","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1530\/ERC-21-0034","volume":"28","author":"O De Rycke","year":"2021","unstructured":"De Rycke O, Walter T, Perrier M, Hentic O, Lombard-Bohas C, Coriat R et al (2021) Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer 28(7):457\u2013466","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"4320_CR78","doi-asserted-by":"publisher","first-page":"R391","DOI":"10.1530\/ERC-20-0227","volume":"27","author":"L de Mestier","year":"2020","unstructured":"de Mestier L, Couvelard A, Blazevic A, Hentic O, de Herder WW, Rebours V et al (2020) Critical appraisal of MGMT in digestive NET treated with alkylating agents. Endocr Relat Cancer 27(10):R391\u2013405","journal-title":"Endocr Relat Cancer"},{"issue":"14","key":"4320_CR79","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/jnci\/djt135","volume":"105","author":"J Zhang","year":"2013","unstructured":"Zhang J, Francois R, Iyer R, Seshadri M, Zajac-Kaye M, Hochwald SN (2013) Current understanding of the molecular biology of pancreatic neuroendocrine tumors. J Natl Cancer Inst 105(14):1005\u20131017","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"4320_CR80","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1002\/cncr.32883","volume":"126","author":"JM Mehnert","year":"2020","unstructured":"Mehnert JM, Bergsland E, O\u2019Neil BH, Santoro A, Schellens JHM, Cohen RB et al (2020) Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study. Cancer 126(13):3021\u20133030","journal-title":"Cancer"},{"issue":"4","key":"4320_CR81","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/path.6348","volume":"264","author":"S Backman","year":"2024","unstructured":"Backman S, Botling J, Nord H, Ghosal S, St\u00e5lberg P, Juhlin CC et al (2024) The evolutionary history of metastatic pancreatic neuroendocrine tumours reveals a therapy driven route to high-grade transformation. J Pathol 264(4):357\u2013370","journal-title":"J Pathol"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04320-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-025-04320-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04320-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T08:02:53Z","timestamp":1770278573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-025-04320-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4320"],"URL":"https:\/\/doi.org\/10.1007\/s00428-025-04320-1","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review was performed after establishing the absence of registered opposition to the use of pathological data in accordance with French bioethics law for retrospective non-interventional review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}